Belgium - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for TREMFYA (guselkumab) from the ongoing Phase 3b GUIDE study, which is designed to understand the impact of early intervention and potential dosing interval flexibility on the long-term disease course in adult patients with moderate to severe plaque psoriasis.

These new data demonstrated that 'super responders'a to guselkumab who received every-16-week dosingb maintained disease control (absolute Psoriasis Area and Severity Index [PASI] score

(C) 2022 Electronic News Publishing, source ENP Newswire